142 related articles for article (PubMed ID: 10203054)
21. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1.
Mascola JR
Vaccine; 2002 May; 20(15):1922-5. PubMed ID: 11983246
[TBL] [Abstract][Full Text] [Related]
22. A genetically engineered live-attenuated simian-human immunodeficiency virus that co-expresses the RANTES gene improves the magnitude of cellular immunity in rhesus macaques.
Shimizu Y; Inaba K; Kaneyasu K; Ibuki K; Himeno A; Okoba M; Goto Y; Hayami M; Miura T; Haga T
Virology; 2007 Apr; 361(1):68-79. PubMed ID: 17157892
[TBL] [Abstract][Full Text] [Related]
23. Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques.
Patterson LJ; Peng B; Abimiku AG; Aldrich K; Murty L; Markham PD; Kalyanaraman VS; Alvord WG; Tartaglia J; Franchini G; Robert-Guroff M
AIDS; 2000 Nov; 14(16):2445-55. PubMed ID: 11101054
[TBL] [Abstract][Full Text] [Related]
24. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1.
Dunn CS; Hurtrel B; Beyer C; Gloeckler L; Ledger TN; Moog C; Kieny MP; Mehtali M; Schmitt D; Gut JP; Kirn A; Aubertin AM
AIDS Res Hum Retroviruses; 1997 Jul; 13(11):913-22. PubMed ID: 9223407
[TBL] [Abstract][Full Text] [Related]
25. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
26. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.
Vogel TU; Reynolds MR; Fuller DH; Vielhuber K; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Marthas ML; Erfle V; Wolinsky SM; Wang C; Allison DB; Rud EW; Wilson N; Montefiori D; Altman JD; Watkins DI
J Virol; 2003 Dec; 77(24):13348-60. PubMed ID: 14645590
[TBL] [Abstract][Full Text] [Related]
27. The critical role of CD4(+) T-cell help in immunity to HIV.
Heeney JL
Vaccine; 2002 May; 20(15):1961-3. PubMed ID: 11983254
[TBL] [Abstract][Full Text] [Related]
28. Effects of virus burden and chemokine expression on immunity to SHIV in nonhuman primates.
Waterman PM; Kitabwalla M; Hatfield GS; Evans PS; Lu Y; Tikhonov I; Bryant JL; Pauza CD
Viral Immunol; 2004; 17(4):545-57. PubMed ID: 15671751
[TBL] [Abstract][Full Text] [Related]
29. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
[TBL] [Abstract][Full Text] [Related]
30. Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys.
Barouch DH; Fu TM; Montefiori DC; Lewis MG; Shiver JW; Letvin NL
Immunol Lett; 2001 Nov; 79(1-2):57-61. PubMed ID: 11595290
[TBL] [Abstract][Full Text] [Related]
31. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
Horton H; Vogel TU; Carter DK; Vielhuber K; Fuller DH; Shipley T; Fuller JT; Kunstman KJ; Sutter G; Montefiori DC; Erfle V; Desrosiers RC; Wilson N; Picker LJ; Wolinsky SM; Wang C; Allison DB; Watkins DI
J Virol; 2002 Jul; 76(14):7187-202. PubMed ID: 12072518
[TBL] [Abstract][Full Text] [Related]
32. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses.
Abel K; Compton L; Rourke T; Montefiori D; Lu D; Rothaeusler K; Fritts L; Bost K; Miller CJ
J Virol; 2003 Mar; 77(5):3099-118. PubMed ID: 12584336
[TBL] [Abstract][Full Text] [Related]
33. Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.
Enose Y; Kita M; Yamamoto T; Suzuki H; Miyake A; Horiuchi R; Ibuki K; Kaneyasu K; Kuwata T; Takahashi E; Sakai K; Shinohara K; Miura T; Hayami M
Arch Virol; 2004 Sep; 149(9):1705-20. PubMed ID: 15593414
[TBL] [Abstract][Full Text] [Related]
34. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.
Fouts TR; Bagley K; Prado IJ; Bobb KL; Schwartz JA; Xu R; Zagursky RJ; Egan MA; Eldridge JH; LaBranche CC; Montefiori DC; Le Buanec H; Zagury D; Pal R; Pavlakis GN; Felber BK; Franchini G; Gordon S; Vaccari M; Lewis GK; DeVico AL; Gallo RC
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E992-9. PubMed ID: 25681373
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
[TBL] [Abstract][Full Text] [Related]
36. Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.
Silverstein PS; Mackay GA; Mukherjee S; Li Z; Piatak M; Lifson JD; Narayan O; Kumar A
J Virol; 2000 Nov; 74(22):10489-97. PubMed ID: 11044093
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection.
Wagner R; Teeuwsen VJ; Deml L; Notka F; Haaksma AG; Jhagjhoorsingh SS; Niphuis H; Wolf H; Heeney JL
Virology; 1998 May; 245(1):65-74. PubMed ID: 9614868
[TBL] [Abstract][Full Text] [Related]
38. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
39. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
40. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
